Abbvie, Mitokinin Partner to Advance PINK1 Program

Abbvie, Mitokinin Partner to Advance PINK1 Program

288641

Abbvie, Mitokinin Partner to Advance PINK1 Program

Abbvie has purchased an exclusive right to acquire Mitokinin, which includes its PINK1 clinical program for the potential treatment of Parkinson’s disease. Under this agreement, Mitokinin will receive an upfront payment and continue to develop its PINK1 compounds by completing an investigational new drug (IND) application and enabling clinical studies. “We’re thrilled to be working with the world-class neuroscience team at AbbVie to bring our PINK1 program forward,” Daniel de Roulet, co-founder and CEO at Mitokinin, said…

You must be logged in to read/download the full post.